ImmuCell (NASDAQ:ICCC) Stock Price Crosses Below Two Hundred Day Moving Average of $4.95

ImmuCell Co. (NASDAQ:ICCC)’s stock price crossed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $4.95 and traded as low as $4.46. ImmuCell shares last traded at $4.49, with a volume of 873 shares traded.

ImmuCell Trading Down 7.4 %

The company has a market capitalization of $35.07 million, a price-to-earnings ratio of -8.80 and a beta of 0.58. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.00 and a current ratio of 2.71. The business’s 50-day simple moving average is $4.69 and its 200-day simple moving average is $4.95.

ImmuCell (NASDAQ:ICCC) last announced its quarterly earnings data on Tuesday, May 14th. The biotechnology company reported ($0.06) earnings per share for the quarter. ImmuCell had a negative net margin of 18.31% and a negative return on equity of 15.21%. The business had revenue of $7.26 million during the quarter.

Hedge Funds Weigh In On ImmuCell

An institutional investor recently bought a new position in ImmuCell stock. Mesirow Financial Investment Management Inc. acquired a new stake in ImmuCell Co. (NASDAQ:ICCC) in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 12,178 shares of the biotechnology company’s stock, valued at approximately $65,000. Mesirow Financial Investment Management Inc. owned approximately 0.16% of ImmuCell as of its most recent SEC filing. 13.47% of the stock is owned by institutional investors and hedge funds.

About ImmuCell

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E.